Real-World Data / Real-Word Evidence Insights

1. HTA, Digital Twins, And Building Clinical Tech That Lasts 4/24/2026

   ISPOR CEO Rob Abbott on HTA-integrated trial design, digital twin evidence gaps, SaMD’s continuous update problem, and the one change he’d mandate for clinical tech.

2. Real-World Evidence And Wearables Are Reshaping Trial Tech 4/22/2026

   ISPOR’s Rob Abbott on why RWE moved to number two in the 2026-2027 HEOR Trends Report, and what wearables, data fragmentation, and HARPER+ mean for clinical platforms.

3. HEOR, AI, And The Future Of Clinical Trial Technology 4/20/2026

   ISPOR CEO Rob Abbott on why HEOR must be in the room when clinical trial tech is built, and what ISPOR’s latest Top 10 HEOR Trends Report means for ClinOps.

4. Clinical Research Has System Sprawl Problem 4/15/2026

   Disconnected systems are strangling clinical trials. Here’s what’s causing the sprawl, why it keeps getting worse, and what needs to change.

5. How Clinical Trial Sites Must Adapt To The Predictive Analytics Era 4/13/2026

   Clinical trial sites are now measured, ranked, and selected by predictive models. Learn how to perform and compete in this data-driven new era.

6. Why Patients Drop Out And How To Stop Them 4/8/2026

   From scheduling friction to silent financial stress, patient dropout derails trials. Here’s what’s causing it and the tech helping sites fight back.

7. Predictive Analytics Is Reshaping How Sponsors Run Clinical Trials 4/6/2026

   Predictive analytics is transforming clinical trial operations, from enrollment forecasting to risk-based monitoring. Here’s what sponsors need to know.

8. AI In Clinical Trials: Real Impact, Real Limits, What's Next 4/2/2026

   Claude’s ClinicalTrials.gov connector changes how sponsors access trial data, but does it change outcomes? A recruitment expert weighs in on impact and what’s still missing.

9. RWD Helps Researchers Include More Patients In Lymphoma Research 4/2/2026

   Andrew Evens, DO, MBA, explores how outcomes research and collaboration across academic networks, registries, and industry partners are advancing more inclusive, data-informed approaches to lymphoma research.

10. RWE Is Ready — Decision Making For Pharmaceuticals Isn't 4/1/2026

    Gorana Capkun of Merck, KGaA, Darmstadt, Germany discusses the growing role of real-world evidence in clinical trials, highlighting a gap between regulatory momentum and pharma adoption— and the challenge of turning data into better decisions.